Immuno-Oncology Drugs Market Segmented by – Current Scenario, Market Drivers Analysis Report Estimated By Global Players Pfizer Inc., Merck & Co., Johnson & Johnson, Novartis International AG, Celldex Therapeutics

Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. It helps the immune system to recognize and target cancer cells. The therapy facilitates long term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology therapy works against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.

For In depth Information Get Sample Copy of this Report at: https://bit.ly/2SrUfu8

Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Global Key Players:

Some major players operating in the immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

Detailed Segmentation:

Global Immuno-Oncology Drugs Market, By Drug Type:
Immune Checkpoint Inhibitors
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Intron A
Proleukin
Cancer Vaccines
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Kymriah
Yescarta

Global Immuno-Oncology Drugs Market, By Cancer Type:
Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma), Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, Head & Neck Cancers

Global Immuno-Oncology Drugs Market, By Geography:
North America,Europe,Asia Pacific,Latin America,Middle East,Africa

Request For Customization of Research Report @ https://bit.ly/2H0nbau

Active Research And Development By Leading Players As Well As Small Innovative Organizations Are Expected To Boost Growth Of The Immune-Oncology Drugs Market:

According to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015. Owing to benefits associated with these therapies, the leading players are actively investing in research and development into this treatment category through various collaborations and individual research studies. For instance, EMD Serono is involved in research and development of immune-oncology drugs and has a few drugs in pipeline such as M7824 (investigational) bifunctional immunotherapy. In 2015, Merck & Co., a leading drug manufacturer and MD Anderson Cancer Center entered into a strategic clinical research collaboration for formers drug Keytruda (Pembrolizumab).

Celsee Diagnostics and IncellDx announced an immuno-oncology research agreement in 2017. Bristol-Myers Squibb is developing immuno-oncology approaches for treatment of colorectal cancer, lung cancer, melanoma, liver cancer, lymphoma, multiple myeloma, and others. Amgen, Inc. is actively involved in immune-oncology research and the company launched an immunotherapy collaboration with Kite Pharma to develop and commercialize chimeric antigen receptor (CAR) T cells in 2015.

High cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.

Market Dynamics:

Global Immuno-oncology drugs market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc. and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost growth of the immuno-oncology drugs market.

Browse Research Report At: https://bit.ly/2Vmou7H

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.